Combination therapy with anti-CD74 and anti-CD20 antibodies provides enhanced toxicity to B-cell diseases
Disclosed are compositions and methods comprising combinations of anti-CD74 and anti-CD20 antibodies or antigen-binding fragments thereof. The antibody combination may also be used with a therapeutic agent that is attached to antibody or fragment thereof or separately administered. The therapeutic agent may be an immunomodulator, a cytokine, a toxin or other known therapeutic agent. Preferably, the anti-CD74 and anti-CD20 antibody or fragment are part of a DNL complex. More preferably, combination therapy with the anti-CD74 and anti-CD20 antibody or fragment is more effective than either antibody alone, or the combination of unconjugated antibodies. Administration of combination induces apoptosis of target cells in diseases in which CD74 is overexpressed, such as solid tumors, B-cell lymphomas or leukemias, autoimmune disease, immune dysfunction disease or diabetes. Preferably, the target cells are B cells.
IBC Pharmaceuticals, Inc.
C A A A A C C C A C C C C A C C C A A C C A C A A A A C A C A A C C A C C
C07K A61K A61P A61K A61K C07K C07K C07K A61K C07K C07K C07K C07K A61K C07K C07K C07K A61K A61P C07K C07K A61K C07K A61P A61P A61K A61K C07K A61K C07K A61K A61K C07K C07K A61K C07K C07K
additional inventional inventional additional inventional additional additional additional inventional inventional additional additional additional inventional additional additional additional inventional inventional additional inventional inventional inventional inventional inventional inventional inventional inventional inventional additional inventional inventional additional inventional inventional additional additional
Edmund A. Chien-Hsing David M.
Rossi Chang Goldenberg